Somatic characteristics and cardiovascular risk factors in growth hormone deficiency

A randomized, double‐blind, placebo‐controlled study of the effect of treatment with recombinant human growth hormone

Datos Bibliográficos

ID19460720
AutoresW Bell (University of Wales Institute Cardiff, autor de correspondencia), J S Davies (0000-0003-2498-6946, University of Wales), W D Evans (0000-0002-7559-1592, University Hospital of Wales), M F Scanlon (University of Wales), Richard Mullen (0000-0002-7920-6233, Cardiff Metropolitan University)
Año2004
Volumen16
Número5
Páginas533-543
Fecha de publicación2004-09-01
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaAmerican Journal of Human Biology (JOURNAL)
Identificadores de la revistaISSN: 1042-0533 • E-ISSN: 1520-6300
EditorialWiley (PUBLISHER • GB)
DOI10.1002/ajhb.20055
PMID15368601
OpenAlexW2158940864
IdiomaEN
Citas recibidas1
Referencias citadas43

The purpose of the present study was to identify the effect of treatment with recombinant human growth hormone (rhGH) on seven somatic characteristics and eight clinical cardiovascular risk factors. Twenty‐seven male and 24 female patients between the ages of 21 and 60 years were examined. The investigation was a double‐blind, placebo‐controlled study of 12 months duration. Patients were assigned randomly to treatment (T) and placebo (P) groups. In the first 6 months group T received rhGH and group P placebo. In the second 6 months both groups received rhGH. Complete data were available for 23 males and 20 females. Increments were calculated between 6 months –BL (increment 1) and 12–6 months (increment 2) in both T and P groups. Apart from the somatotype, data were analysed with a 2 × 2 mixed analysis of variance (ANOVA) using treatment (rhGH and placebo) and time (increments 1 and 2). Somatotype data were analysed using a 2 × 3 multivariate ANOVA. Three significant interactions were identified in males: waist circumference ( P = 0.006), trunk fat ( P = 0.0001), and conicity index ( P = 0.001). The only significant interaction in females was trunk fat ( P = 0.006). In general, treatment and placebo groups responded differently by time and treatment. Responses were similar in males and females. In the first 6 months when group P was on placebo, waist circumference, trunk fat, and conicity index increased slightly; with group T on rhGH somatic variables declined markedly. In the second 6 months when both groups received rhGH there was a marked decline in group P and a continued decline (but less steeply) in group T. In males there were significant decreases in endomorphy in group T and increases in mesomorphy in group P. In females the somatotype remained stable. There were no significant interactions in clinical cardiovascular risk factors in either males or females. Favourable responses occurred in male and female lipid profiles, although these were not significant. It was concluded that in males waist circumference, trunk fat, conicity index, and somatotype responded significantly to treatment with rhGH; in females the only significant response was trunk fat. Am. J. Hum. Biol. 16:533–543, 2004. © 2004 Wiley‐Liss, Inc

Alternative medicine · Biology · Double blind · Gene · Growth hormone · Hormone · Human growth hormone · Pathology · Placebo · Placebo-controlled study · Randomized controlled trial · Recombinant DNA · Somatic cell · Diet and metabolism studies · Growth Hormone and Insulin-like Growth Factors · Lipid metabolism and disorders · Medicine · Endocrinology · Genetics · Internal Medicine